New antibody combo shows promise for Hard-to-Treat myeloma

NCT ID NCT04910568

Ongoing Disease control Sponsor: Genentech, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 07, 2026 · Updated 4 times

Summary

This early-phase trial is testing an experimental antibody called cevostamab, either alone or combined with other drugs (pomalidomide, daratumumab, and dexamethasone), in 126 people with multiple myeloma that has returned or stopped responding to treatment. The main goals are to find the safest dose and check for side effects. Researchers will also look at how well the cancer responds and how long any benefit lasts.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cevostamab (an experimental antibody), pomalidomide, daratumumab, dexamethasone, tocilizumab
What this could lead to: If successful, this could point toward a new treatment option for people with multiple myeloma that has stopped responding to other therapies.
What could go wrong: This is an early-phase trial with only 126 participants, so results may not apply to everyone. Side effects like cytokine release syndrome are possible, and the drug may not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

A.O. Spedali Civili Di Brescia-P.O. Spedali Civili

Brescia, Lombardy, 25123, Italy
Asst Papa Giovanni Xxiii

Bergamo, Lombardy, 24127, Italy
CHU de Poitiers - La Miletrie

Poitiers, 86021, France
City of Hope

Duarte, California, 91010, United States
City of Hope - Lennar Foundation Cancer Center

Irvine, California, 92618, United States
Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center

Denver, Colorado, 80218, United States
Cross Cancer Institute

Edmonton, Alberta, T6G 1Z2, Canada
Fakultni Nemocnice Ostrava

Ostrava, 708 52, Czechia
Hamilton Health Sciences

Hamilton, Ontario, L8V 5C2, Canada
Hospital General Universitario Gregorio Marañon

Madrid, 28009, Spain
Hospital Universitari Vall d'Hebron

Barcelona, 08035, Spain
Karmanos Cancer Institute.

Detroit, Michigan, 48201, United States
Peter MacCallum Cancer Centre

Melbourne, Victoria, 3002, Australia
Pratia Onkologia Katowice

Katowice, 41-500, Poland
Rambam Medical Center

Haifa, 3109601, Israel
Rigshospitalet

København Ø, 2100, Denmark
Royal Marsden Hospital

Sutton, SW3 6JJ, United Kingdom
Samsung Medical Center

Seoul, 06351, South Korea
Seoul National University Hospital

Seoul, 03080, South Korea
The Alfred Hospital

Melbourne, Victoria, 3004, Australia
University College London Hospitals NHS Foundation Trust

London, W1T 7HA, United Kingdom
University Health Network

Toronto, Ontario, M5G 2M9, Canada
Washington University School of Medicine

St Louis, Missouri, 63110, United States
Yamagata University Hospital

Yamagata, 990-9585, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.